Elucidation of the oncogenes involved in human breast cancer may have important prognostic and therapeutic implications as is already documented for erbB-2/neu/Her.2. We now seek to investigate the involvement of each of the known erbB family members in a series of human breast Carcinoma cell lines by measuring their protein expression levels, constitutive phosphorylation and physical interactions. We will also study the mechanisms responsible for cooperative transformation between erbB-2 and erbB-3 at a molecular and biochemical level and mechanisms causing coactivation of these receptors in some breast tumors. Recent studies have revealed new oncogenic members of the ras family, TC21 and R-ras, and our preliminary studies demonstrate striking TC21 overexpression in a human breast tumor cell line. We seek to develop further evidence of the involvement of ras-like genes in breast tumors using antibodies which specifically detect their overexpression and PCR-based molecular genetic approaches to search for oncogenic activating mutations. The possibility that these new ras genes may mediate transforming/proliferative signaling by erbB family members will also be explored by determining their ability to cooperate for transformation and increase GTP binding in response to different erbB family receptors. Breast epithelial cell transfectants will be established to test the oncogenic potential of the oncogenes implicated in a relevant experimental model. The knowledge gained should be useful in assessing the efficacy of new therapeutic modalities in breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA068425-03
Application #
6237600
Study Section
Project Start
1997-09-30
Project End
1998-08-31
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
3
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Navin, Nicholas E; Hicks, James (2010) Tracing the tumor lineage. Mol Oncol 4:267-83
Ueda, Yukiko; Su, Yingjun; Richmond, Ann (2007) CCAAT displacement protein regulates nuclear factor-kappa beta-mediated chemokine transcription in melanoma cells. Melanoma Res 17:91-103
Solit, David B; Scher, Howard I; Rosen, Neal (2003) Hsp90 as a therapeutic target in prostate cancer. Semin Oncol 30:709-16
Mu, David; Chen, Liyun; Zhang, Xiping et al. (2003) Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene. Cancer Cell 3:297-302
Solit, David B; Basso, Andrea D; Olshen, Adam B et al. (2003) Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 63:2139-44
Hamaguchi, Masaaki; Meth, Jennifer L; von Klitzing, Christine et al. (2002) DBC2, a candidate for a tumor suppressor gene involved in breast cancer. Proc Natl Acad Sci U S A 99:13647-52
Munster, Pamela N; Marchion, Douglas C; Basso, Andrea D et al. (2002) Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway. Cancer Res 62:3132-7
Subbaramaiah, Kotha; Norton, Larry; Gerald, William et al. (2002) Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 277:18649-57
Basso, Andrea D; Solit, David B; Munster, Pamela N et al. (2002) Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 21:1159-66
Solit, David B; Zheng, Fuzhong F; Drobnjak, Maria et al. (2002) 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8:986-93

Showing the most recent 10 out of 51 publications